TWI404716B - 酞嗪酮(phthalazinone)衍生物 - Google Patents
酞嗪酮(phthalazinone)衍生物 Download PDFInfo
- Publication number
- TWI404716B TWI404716B TW096138353A TW96138353A TWI404716B TW I404716 B TWI404716 B TW I404716B TW 096138353 A TW096138353 A TW 096138353A TW 96138353 A TW96138353 A TW 96138353A TW I404716 B TWI404716 B TW I404716B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- cancer
- water
- fluoro
- hexahydropyrazine
- Prior art date
Links
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 title 1
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 109
- 150000001875 compounds Chemical class 0.000 claims description 88
- 229940126062 Compound A Drugs 0.000 claims description 76
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 41
- 239000002904 solvent Substances 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 30
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims description 28
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims description 28
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 28
- 239000000725 suspension Substances 0.000 claims description 27
- 108020004414 DNA Proteins 0.000 claims description 22
- -1 4-[3-(4-cyclopropanecarbonyl-hexahydropyrazine-1-carbonyl)-4-fluoro-benzyl]-2H-pyridazine Chemical compound 0.000 claims description 19
- 102000052609 BRCA2 Human genes 0.000 claims description 17
- 108700020462 BRCA2 Proteins 0.000 claims description 17
- 101150008921 Brca2 gene Proteins 0.000 claims description 17
- 230000008439 repair process Effects 0.000 claims description 17
- 102000036365 BRCA1 Human genes 0.000 claims description 14
- 108700020463 BRCA1 Proteins 0.000 claims description 14
- 101150072950 BRCA1 gene Proteins 0.000 claims description 14
- 239000013078 crystal Substances 0.000 claims description 13
- 230000001419 dependent effect Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000002950 deficient Effects 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 230000037361 pathway Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 230000005865 ionizing radiation Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 3
- 206010029350 Neurotoxicity Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 3
- 230000001668 ameliorated effect Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000037906 ischaemic injury Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000007135 neurotoxicity Effects 0.000 claims description 3
- 231100000228 neurotoxicity Toxicity 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 230000005782 double-strand break Effects 0.000 description 15
- 230000006801 homologous recombination Effects 0.000 description 15
- 238000002744 homologous recombination Methods 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000012661 PARP inhibitor Substances 0.000 description 10
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 230000002194 synthesizing effect Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 238000004821 distillation Methods 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- JCLURXKCGFCJSS-UHFFFAOYSA-N C1C(=O)C=CN(N1)CC2=CC(=C(C=C2)F)C#N Chemical compound C1C(=O)C=CN(N1)CC2=CC(=C(C=C2)F)C#N JCLURXKCGFCJSS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- KIALFUYSJAAJSU-UHFFFAOYSA-N cyclopropyl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CC1 KIALFUYSJAAJSU-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229940100198 alkylating agent Drugs 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 238000001144 powder X-ray diffraction data Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 3
- KCNPNQHPXMBYDK-UHFFFAOYSA-N 2-fluoro-5-[(5-oxo-1,6-dihydropyridazin-2-yl)methyl]benzoic acid Chemical compound FC1=C(C(=O)O)C=C(C=C1)CN1NCC(C=C1)=O KCNPNQHPXMBYDK-UHFFFAOYSA-N 0.000 description 3
- DYNFCHNNOHNJFG-UHFFFAOYSA-N 2-formylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C=O DYNFCHNNOHNJFG-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 241000282520 Papio Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033590 base-excision repair Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 2
- IANXAXNUNBAWBA-UHFFFAOYSA-N 2,2,3-trimethylundecane Chemical compound CCCCCCCCC(C)C(C)(C)C IANXAXNUNBAWBA-UHFFFAOYSA-N 0.000 description 2
- WIXKRKWSXDVKIX-UHFFFAOYSA-N 3-diethoxyphosphoryl-3h-2-benzofuran-1-one Chemical compound C1=CC=C2C(P(=O)(OCC)OCC)OC(=O)C2=C1 WIXKRKWSXDVKIX-UHFFFAOYSA-N 0.000 description 2
- 102100027161 BRCA2-interacting transcriptional repressor EMSY Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 231100001074 DNA strand break Toxicity 0.000 description 2
- 101150029113 EMSY gene Proteins 0.000 description 2
- 101001057996 Homo sapiens BRCA2-interacting transcriptional repressor EMSY Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000019994 cava Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- CZHYKKAKFWLGJO-UHFFFAOYSA-N dimethyl phosphite Chemical compound COP([O-])OC CZHYKKAKFWLGJO-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- FCWLIFWRJMCIAC-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl)phosphonic acid Chemical compound C1=CC=C2C(P(O)(=O)O)OC(=O)C2=C1 FCWLIFWRJMCIAC-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HVCFCNAITDHQFX-UHFFFAOYSA-N 1-cyclopropylethanone Chemical compound CC(=O)C1CC1 HVCFCNAITDHQFX-UHFFFAOYSA-N 0.000 description 1
- ATBJTIJUTXNSHP-UHFFFAOYSA-N 2,3,4,5-tetrafluorofuran Chemical compound FC=1OC(F)=C(F)C=1F ATBJTIJUTXNSHP-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MMPHWTMMVPBHRZ-UHFFFAOYSA-N 2-fluoro-5-[(3-oxo-2-benzofuran-1-ylidene)methyl]benzonitrile Chemical compound C1=C(C#N)C(F)=CC=C1C=C1C2=CC=CC=C2C(=O)O1 MMPHWTMMVPBHRZ-UHFFFAOYSA-N 0.000 description 1
- PAXLJNGPFJEKQX-UHFFFAOYSA-N 2-fluoro-5-[(4-oxo-3h-phthalazin-1-yl)methyl]benzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=C1 PAXLJNGPFJEKQX-UHFFFAOYSA-N 0.000 description 1
- PYBHNYNUDGSMIJ-UHFFFAOYSA-N 2-fluoro-5-sulfanylbenzonitrile Chemical compound Fc1ccc(S)cc1C#N PYBHNYNUDGSMIJ-UHFFFAOYSA-N 0.000 description 1
- FNUBKINEQIEODM-UHFFFAOYSA-N 3,3,4,4,5,5,5-heptafluoropentanal Chemical compound FC(F)(F)C(F)(F)C(F)(F)CC=O FNUBKINEQIEODM-UHFFFAOYSA-N 0.000 description 1
- KEKUNQAVGWOYDW-UHFFFAOYSA-N 3-dimethoxyphosphoryl-3h-2-benzofuran-1-one Chemical compound C1=CC=C2C(P(=O)(OC)OC)OC(=O)C2=C1 KEKUNQAVGWOYDW-UHFFFAOYSA-N 0.000 description 1
- IHTFSBAUENZVAX-UHFFFAOYSA-N 3-methylsulfanylbenzonitrile Chemical compound CSC1=CC=CC(C#N)=C1 IHTFSBAUENZVAX-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- MFFUYEOGICAKCK-UHFFFAOYSA-N 4-[[4-fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2h-phthalazin-1-one Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N1CCNCC1 MFFUYEOGICAKCK-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102100034490 DNA repair and recombination protein RAD54B Human genes 0.000 description 1
- 102100039116 DNA repair protein RAD50 Human genes 0.000 description 1
- 102100033934 DNA repair protein RAD51 homolog 2 Human genes 0.000 description 1
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 description 1
- 102100034483 DNA repair protein RAD51 homolog 4 Human genes 0.000 description 1
- 102100027830 DNA repair protein XRCC2 Human genes 0.000 description 1
- 102100027829 DNA repair protein XRCC3 Human genes 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- NHYJZSCLQXGNBU-UHFFFAOYSA-N FC(C(C(F)(F)F)O)(F)F.FC1=CC=CC=C1 Chemical compound FC(C(C(F)(F)F)O)(F)F.FC1=CC=CC=C1 NHYJZSCLQXGNBU-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000712511 Homo sapiens DNA repair and recombination protein RAD54-like Proteins 0.000 description 1
- 101001132263 Homo sapiens DNA repair and recombination protein RAD54B Proteins 0.000 description 1
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 description 1
- 101001132307 Homo sapiens DNA repair protein RAD51 homolog 2 Proteins 0.000 description 1
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 description 1
- 101001132266 Homo sapiens DNA repair protein RAD51 homolog 4 Proteins 0.000 description 1
- 101000649306 Homo sapiens DNA repair protein XRCC2 Proteins 0.000 description 1
- 101000949825 Homo sapiens Meiotic recombination protein DMC1/LIM15 homolog Proteins 0.000 description 1
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 description 1
- 101000981336 Homo sapiens Nibrin Proteins 0.000 description 1
- 101001046894 Homo sapiens Protein HID1 Proteins 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000046961 MRE11 Homologue Human genes 0.000 description 1
- 108700019589 MRE11 Homologue Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100035285 Meiotic recombination protein DMC1/LIM15 homolog Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100031897 NACHT, LRR and PYD domains-containing protein 2 Human genes 0.000 description 1
- 101100355599 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-11 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- RKALMGZHSSPENK-UHFFFAOYSA-L O=C(C1CC1)[Ru](Cl)Cl Chemical compound O=C(C1CC1)[Ru](Cl)Cl RKALMGZHSSPENK-UHFFFAOYSA-L 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108091026813 Poly(ADPribose) Proteins 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001195 RAD51 Human genes 0.000 description 1
- 101150006234 RAD52 gene Proteins 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 102000053062 Rad52 DNA Repair and Recombination Human genes 0.000 description 1
- 108700031762 Rad52 DNA Repair and Recombination Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 101710179516 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 102100023931 Transcriptional regulator ATRX Human genes 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010074310 X-ray repair cross complementing protein 3 Proteins 0.000 description 1
- UMIBOLGAEOTJMJ-UHFFFAOYSA-N [Cl-].C1(CC1)C(=O)[PH3+] Chemical compound [Cl-].C1(CC1)C(=O)[PH3+] UMIBOLGAEOTJMJ-UHFFFAOYSA-N 0.000 description 1
- DDSZWBCJXDRQDU-UHFFFAOYSA-N [N].C1CCNCC1 Chemical compound [N].C1CCNCC1 DDSZWBCJXDRQDU-UHFFFAOYSA-N 0.000 description 1
- ZKINYYBCBNPOBO-UHFFFAOYSA-N [N].O=C1C=CC=NN1 Chemical compound [N].O=C1C=CC=NN1 ZKINYYBCBNPOBO-UHFFFAOYSA-N 0.000 description 1
- SMIXPCGBYDMZDV-UHFFFAOYSA-K [Ru](Cl)(Cl)Cl.C1CC1 Chemical compound [Ru](Cl)(Cl)Cl.C1CC1 SMIXPCGBYDMZDV-UHFFFAOYSA-K 0.000 description 1
- UEGZKQNSTOCSEV-UHFFFAOYSA-L [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(F)=O.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UEGZKQNSTOCSEV-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- BFBMDIKDROEXQH-UHFFFAOYSA-N cyclopropanecarbohydrazide;hydrochloride Chemical compound Cl.NNC(=O)C1CC1 BFBMDIKDROEXQH-UHFFFAOYSA-N 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- AXLHVTKGDPVANO-UHFFFAOYSA-N methyl 2-amino-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound COC(=O)C(N)CNC(=O)OC(C)(C)C AXLHVTKGDPVANO-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 101150071637 mre11 gene Proteins 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- COMSJHPCIFMSDX-UHFFFAOYSA-N n,n-dimethylacetamide;n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CN(C)C(C)=O.CCN(C(C)C)C(C)C COMSJHPCIFMSDX-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000005731 poly ADP ribosylation Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- JZVZOOVZQIIUGY-UHFFFAOYSA-M sodium;tridecanoate Chemical compound [Na+].CCCCCCCCCCCCC([O-])=O JZVZOOVZQIIUGY-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N trifluorotoluene Substances FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Description
本發明係關於特定酞嗪酮衍生物之晶體形式及合成其之改良方法、該合成中之中間體及醫藥組合物及該晶體形式之用途。
哺乳動物酵素PARP(一種113-kDa之多區域蛋白質)涉及藉助其識別並快速結合DNA單鏈或雙鏈斷裂之能力來遞送DNA損傷之信號(D'Amours等人,Biochem.J.,342,249-268(1999))。
許多觀察已得出以下結論:PARP參與各種與DNA相關之作用(包括基因擴增、細胞***、分化、凋亡、DNA鹼基切除修復)且亦影響端粒長度及染色體穩定性(d'Addadi Fagagna等人,Nature Gen.
,23(1)
,76-80(1999))。
對PARP調節DNA修復及其他過程之機制的研究確定了其在形成細胞核內聚(ADP-核糖)鏈中之重要性(Althaus,F.R.及Richter,C.,ADP-Ribosylation of Proteins:Enzymology and Biological Significance,Springer-Verlag,Berlin(1987))。與DNA結合並經活化之PARP利用NAD於多種核靶蛋白(包括拓撲異構酶、組蛋白及PARP自身)上合成聚(ADP-核糖)(Rhun等人,Biochem.Biophys.Res.Commun.
,245
,1-10(1998))。
聚(ADP-核糖基)化作用亦與惡性轉化相關。舉例而言,在SV40轉化之成纖維細胞的分離細胞核中PARP活性較高,而且白血病細胞及結腸癌細胞二者均顯示較同種正常白細胞及結腸黏膜中為高之酵素活性(Miwa等人,Arch.Biochem.Biophys.
,181
,313-321(1977);Burzio等人,Proc.Soc.Exp.Bioi.Med.
,149
,933-938(1975);及Hirai等人,Cancer Res.
,43
,3441-3446(1983))。
許多低分子量PARP抑制劑已用於闡釋聚(ADP-核糖基)化作用在DNA修復中之功能性作用。在經烷基化試劑處理之細胞中,PARP之抑制會導致DNA鏈斷裂及細胞殺傷顯著增加(Durkacz等人,Nature
,283
,593-596(1980);Berger,N.A.,Radiation Research
,101
,4-14(1985))。
隨後,該等抑制劑顯示可藉由抑制潛在致死損傷之修復來增強輻射反應之作用(Ben-Hur等人,British Journal of Cancer
,49
(Suppl.VI),34-42(1984);Schlicker等人,Int.J.Radiat.Bioi.
,75
,91-100(1999))。據報道,PARP抑制劑在射線增敏性乏氧腫瘤細胞中有效(美國專利第5,032,617號;美國專利第5,215,738號及美國專利第5,041,653號)。
此外,PARP基因剔除(PARP -/-)動物響應烷基化試劑及γ-輻照展示基因組不穩定性(Wang等人,Genes Dev.
,9
,509-520(1995);Menissier de Murcia等人,Proc.Natl.Acad.Sci.USA
,94
,7303-7307(1997))。
PARP之作用亦展示於一些血管疾病、敗血性休克、缺血性損傷及神經毒性中(Cantoni等人,Biochim.Biophys.Acta
,1014
,1-7(1989);Szabo等人,J.Clin.Invest.
,100
,723-735(1997))。導致DNA鏈斷裂(其隨後藉由PARP識別)之氧自由基DNA損傷係該等如在PARP抑制劑研究中所示之疾病狀態的主要影響因素(Cosi等人,J.Neurosci.Res.
,39
,38-46(1994);Said等人,Proc.Natl.Acad.Sci.U.S.A.
,93
,4688-4692(1996))。近來,已證明PARP在出血性休克之發病機理中起作用(Liaudet等人,Proc.Natl.Acad.Sci.U.S.A.
,97(3)
,10203-10208(2000))。
亦已證明哺乳動物細胞之有效逆轉錄病毒感染可藉由抑制PARP活性來阻斷。已顯示,重組逆轉錄載體感染之此抑制可發生於各種不同細胞類型中(Gaken等人,J.Virology
,70(6)
,3992-4000(1996))。因此,人們已經開發出PARP抑制劑以用於抗病毒治療及癌症治療(WO 91/18591)。
另外,已推測PARP抑制可延遲人類成纖維細胞中老化特徵之開始(Rattan and Clark,Biochem.Biophys.Res.Comm.
,201(2)
,665-672(1994))。此可能與PARP在控制端粒功能中所起之作用相關(d'Adda di Fagagna等人,Nature Gen.
,23(1)
,76-80(1999))。
WO 2004/080976揭示許多酞嗪酮衍生物、其抑制PARP之活性、及其在治療癌症中之重要用途(無論其作為放射治療或化學治療之輔助藥劑還是作為單獨藥劑)。
WO 2005/053662闡述PARP抑制劑(尤其酞嗪酮衍生物)作為鹼基切除修復(BER)抑制劑之用途。其闡述該等抑制劑在製造藥物中之用途,該等藥物用於治療同源重組(HR)依賴性DNA DSB修復活性缺陷之癌症、尤其用於治療具有BRCA1及/或BRCA2缺陷表型之癌症。
WO 2004/080976中所揭示之4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮(化合物A):
尤其令人感興趣。
在WO 2004/080976中,化合物A係作為許多文庫化合物中之一自4-[4-氟-3-(六氫吡嗪-1-羰基)-苄基]-2H-酞嗪-1-酮(化合物B)藉由以下合成:
將環丙烷羰醯氯:
添加於(B)溶於二氯甲烷之溶液中,隨後添加Hnig鹼(N,N-二異丙基乙基胺)。
該反應在室溫下邊攪拌邊實施達16小時,且所得化合物藉由製備型HPLC純化。
六氫吡嗪衍生物(B)係藉由以下製備:使用6M HCl及乙醇脫保護4-[2-氟-5-(4-氧代-3,4-二氫-酞嗪-1-基甲基)-苯甲醯基]-六氫吡嗪-1-甲酸第三丁基酯(化合物C):
去保護達1小時,隨後用氨鹼化至pH為9,並將其萃取入二氯甲烷中。
經Boc-保護之六氫吡嗪衍生物(C)係自2-氟-5-(4-氧代-3,4-二氫-酞嗪-1-基甲基)-苯甲酸(化合物D)藉由以下製備:
添加六氫吡嗪-1-甲酸第三丁基酯:
六氟磷酸2-(1H-苯并***-1-基)-1,1,3,3-四甲基脲尿鎓(HBTU)及存於二甲基乙醯胺中之N,N-二異丙基乙基胺,隨後攪拌18小時。
化合物A之特定形式可具有有利性質,例如,就其溶解性及/或其穩定性及/或其生物利用度及/或其雜質分佈圖及/或其過濾特性及/或其乾燥特性及/或其缺乏吸水性、及/或其可更容易地處理及/或微粒化及/或形成錠劑而言。亦期望有一種適於大規模合成化合物A之改良合成方法。
因此,本發明之第一態樣提供實質上呈晶體形式、且尤其呈形式A之4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮(化合物A)。
上文所用之"實質上呈晶體形式"意指至少50重量%、較佳至少70重量%、80重量%或90重量%之化合物A呈晶體形式。在一些實施例中,至少95重量%、99重量%或甚至99.5重量%或更高重量百分數呈晶體形式。
呈晶體形式A之化合物A具有在以下位置處包含特定峰之X射線繞射圖案(λ=1.5418):
呈晶體形式A之化合物A亦可具有下列額外峰之X射線繞射圖案(λ=1.5418):
呈晶體形式A之化合物A之特徵亦在於三個或更多選自上述10個峰列表中之峰的任何組合。
呈形式A之化合物A的代表性粉末XRD圖案展示於圖3中。
不欲受限於理論,化合物A能容易地形成其中溶劑分子可佔據晶格中之位置的結構。該等溶劑合物(本質上不必按化學計量)可由一種純溶劑合物(例如,化合物A的甲醇合物、及化合物A的四氫呋喃合物)構成或可能由一種以上溶劑組份(例如,甲醇及二乙基醚)構成。該等溶劑分子通常位於由化合物A分子所產生之洞穴內。在某些情況下,該等洞穴之體積具有足夠撓性以納入一系列溶劑,此使得材料之整體結構幾乎無變化,且因此在XRPD反射中僅有微小位移。
溶劑合物(包括彼等共享相同整體結構者)係自以下溶劑之溶液熟化及結晶實驗產生:二氯甲烷、乙酸乙酯、甲醇、乙醇、異丙醇、2-丁酮、第三丁基甲基醚、甲苯、四氫呋喃、水、環己烷、環丙基甲基酮、1,2二氯乙烷、三氟乙酸乙酯、氟苯六氟-異-丙醇、甲基九氟丁基醚、2-甲基-1-丙醇、硝基甲烷、丙腈、三氯乙烯、ααα-三氟甲苯、庚烷、二氧雜環己烷、乙腈,該等可作為純溶劑或與另一溶劑組合。最普通之溶劑合物結構的X-射線繞射圖案展示於圖4中,且通常包含下列位置處之最強峰:
應瞭解,圖中所示之峰的相對強度可根據測試下樣品之定向及所使用儀器之類型及設定而變化,因此本文所包括之XRD痕跡之強度係闡釋性的且並非意欲用於絕對比較。
化合物A之形式A實質上不含溶劑。本文所用術語"實質上不含溶劑"意指僅具有可忽略量之任何溶劑的形式,例如,具有總共0.5重量%或更少之任何溶劑的形式。任何溶劑(包括水)之總量可係0.25重量%、0.1重量%、0.05重量%或0.025重量%或更低。
化合物A之形式A亦可使用DSC表徵。當以10℃/分鐘之速率自25℃加熱至325℃時,化合物A之形式A在210.1℃±1℃下開始熔化。呈形式A之化合物A的代表性DSC痕跡於圖5中顯示。
本發明之第二態樣提供一種獲得呈晶體形式A之4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮(化合物A)之方法,其包括使化合物A在一種溶劑中結晶及隨後用替代劑自晶體形式中替代該溶劑。該替代劑可係水或C1-2
醇與水之混合物。
在第一實施例中,該方法包括以下步驟:(i)自一溶劑中結晶析出4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮(化合物A);(ii)若初始溶劑不為乙醇,則用乙醇處理該晶體化合物A;(iii)用水處理該晶體化合物A以移除所捕獲之乙醇;(iv)乾燥所得產物。
用於最初結晶之溶劑可係(例如)二氯甲烷或乙腈。
獲得形式A之方法通常可涉及溶劑替換。已發現化合物A以在晶格內形成能捕獲溶劑之通道的方式結晶,因此使該等溶劑難以移除。
若化合物A結晶中所用溶劑為二氯甲烷,則尤其可使用第一實施例之方法。用乙醇作為溶劑來交換作為溶劑之二氯甲烷的步驟可藉由在乙醇存在下於常壓下蒸餾化合物A的溶液來實施。當頭部溫度達到乙醇沸點(例如,至少73℃)時完成此交換。具體而言,該交換可藉由蒸餾出大部分DCM、然後添加大量乙醇來實施。然後繼續蒸餾,同時用等體積乙醇替換餾出物批料。
可藉由將溶液冷卻至低於15℃、較佳低於10℃、且更佳至約8℃來實施化合物A自乙醇溶劑之結晶。然後可藉由過濾將化合物A之晶體自溶液移出。
可用水處理該晶體化合物A以移除所捕獲乙醇,此係藉由將該晶體材料懸浮於水中並於回流下加熱足夠長之時間(例如至少3小時,且較佳至少約4小時)來實施。可藉由過濾將該晶體化合物A自存於水中之懸浮液中移出。
上述步驟所得產物之乾燥可容易地達成。舉例而言,藉由在一烘箱中於至少60℃、較佳約70℃之溫度下加熱該產物來達成。
在另一該實施例中,該方法包含下列步驟:(i)獲得包含溶劑呈晶體形式之化合物A;(ii)若在合成呈晶體形式之化合物A中所用初始溶劑不為水與C1-2
醇(即甲醇、乙醇)之混合物,則用水與C1-2
醇之混合物處理呈晶體形式之化合物A;(ii)乾燥所得產物。
可用水與C1-2
醇之混合物進一步處理所得產物,並將其乾燥以進一步分離呈晶體形式A之化合物A。
水與C1-2
醇之混合物較佳以體積計在2:1至1:2之範圍內,且更佳以體積計在1.5:1至1:1.5之範圍內。尤其較佳之混合物係1份水:1.2份C1-2
醇。另一尤其較佳之混合物係2份水:1份C1-2
醇。該C1-2
醇較佳為乙醇。
如上所述,可藉由使化合物A自溶劑中結晶來獲得呈晶體形式之化合物A。
步驟(ii)之溶劑處理可藉由將化合物A懸浮於水與C1-2
醇之混合物中並邊攪拌邊加熱回流來實施。此後,可將其冷卻至55℃與65℃之間並(例如)藉助矽藻土墊過濾。用水與C1-2
醇之混合物洗滌濾墊,然後於常壓(通常1 atm)、或高於常壓下蒸餾。停止蒸餾獲得懸浮液,將該懸浮液置於室溫下,隨後過濾。用水洗滌所得濾餅。
上述步驟所得產物之乾燥可容易地達成。舉例而言,藉由在烘箱中於至少50℃、較佳約60℃之溫度下加熱該產物來達成。
可以類似於上述之方式進行進一步處理。
在第三實施例中,該方法包括:(i)將化合物A懸浮於作為溶劑之水與C1-2
醇之混合物中;(ii)將該懸浮液加熱回流;(iii)冷卻該溶液並用呈形式A之化合物A種晶種;(iv)乾燥所得產物。
可用水與C1-2
醇之混合物進一步處理所得產物,並將其乾燥以進一步分離呈晶體形式A之化合物A。
水與C1-2
醇之混合物較佳以體積計在2:1至1:5之範圍內,且更佳以體積計在1:2至1:4之範圍內。尤其較佳之混合為1份水:3份C1-2
醇。該C1-2
醇較佳為乙醇。
步驟(iii)可包括將溶液冷卻至65℃與75℃之間(例如70℃)並(例如)藉助矽藻土墊過濾。用水與C1-2
醇之混合物洗滌濾墊,然後將其蒸餾(例如,在常壓、或更高壓力下)。將所得濾液冷卻至40℃與50℃之間(例如45℃)後,可添加晶種。在2與3小時之間(例如2.5小時)將所得懸浮液冷卻至周溫(例如20℃)並於該溫度下維持足夠長時間以產生結晶。該時間可係12小時至24小時之間,且可約16小時。此階段結束後,可進一步添加水。該量可約等於所存在溶劑(水及C1-2
醇)之總體積且應(例如)在4至6(例如5)小時內緩慢添加。添加水後,將懸浮液維持在周溫下(例如)達2小時。
然後可過濾該懸浮液,用C1-2
醇及水之混合物(比率介於1:3與1:2之間,例如1:2.3)洗滌所得濾餅。
上述步驟所得產物之乾燥可容易地達成。舉例而言,藉由在烘箱中於真空下在40℃與60℃間之溫度下加熱該產物來達成。
本發明之第三態樣提供一種自化合物B合成化合物A之方法,其包括如下步驟:(i)以控制方式將溶於適當有機溶劑(例如DCM(二氯甲烷))中之三乙基胺及環丙烷羰醯氯之預混合溶液添加至溶於相同有機溶劑之化合物B中,同時將溶液溫度控制在低於20℃。
在一些實施例中,該方法進一步包括下列步驟:(ii)攪動(例如攪拌)來自(i)之所得溶液直至反應完成,同時將溶液溫度維持在低於20℃。
步驟(i)中之添加可以逐滴方式實施。
該方法較WO 2004/080976中所述之方法控制更嚴格,此使得醯基氯之加成更具位置選擇性。先前技術控制較少之方法可導致醯基氯加成至酞嗪酮態氮及/或氧、以及期望之六氫吡啶態氮上。
較佳地,上述方法在氮蒙氣下實施。
更佳地,階段(ii)中溶液之溫度保持在10℃與15℃之間。
上述反應之產物較佳藉由至少一步水洗滌步驟處理。更佳地,該處理包括最初及最終之水洗滌步驟、及用稀酸(例如5%檸檬酸溶液)、隨後用稀鹼(例如5%碳酸鈉溶液)之中間洗滌步驟。
本發明之第四態樣提供一種自化合物D合成化合物A之方法,其包括使化合物D與1-(環丙基羰基)六氫吡嗪、或其無機酸鹽在醯胺偶合劑及鹼(例如,胺(例如三級胺,諸如二異丙基乙基胺))之存在下反應。
該無機酸鹽可係(例如)鹽酸鹽。
1-(環丙基羰基)六氫吡嗪、或其無機酸鹽至化合物D之添加可在任何適宜溶劑(例如,乙腈)中實施。該醯胺偶合劑較佳為六氟磷酸2-(1H-苯并***-1-基)-1,1,3,3-四甲基脲鎓(HBTU)。其較佳在一段時間內(例如30分鐘)將1-(環丙基羰基)六氫吡嗪、或其無機酸鹽之溶液添加至二異丙基乙基胺及化合物D中。可將所得溶液之溫度維持在25℃或更低(或20℃或更低,例如18℃)。在其添加完後,可將所得溶液靜置一段時間。較佳之溫度狀態係將溶液在室溫下維持2小時。
可藉由將溶液冷卻至低於10℃(或低於5℃,例如3℃)達一段時間(例如1小時)、隨後過濾來將所得化合物A自溶液中移出。可用(例如)冷乙腈洗滌所得化合物A。
WO 2004/080976中揭示了下述至化合物D之路線:
於0℃下將亞磷酸二甲酯逐滴添加至甲醇鈉於甲醇中之溶液中。然後將2-羧基苯甲醛(H)逐份添加至作為溶於甲醇中之漿液的反應混合物中,同時溫度保持低於5℃。在1小時內將所得淺黃色溶液升溫至20℃。將甲烷磺酸逐滴添加至該反應中並於真空下蒸發所得白色懸浮液。用水使白色殘餘物驟冷並將其萃取至氯仿中。將合併的有機萃取物用水洗滌、經MgSO4
乾燥、並於真空下蒸發,獲得白色固體狀(3-氧代-1,3-二氫-異苯并呋喃-1-基)膦酸二甲基酯(G)(產率:95%)。然後其可不經進一步純化用於下一階段。
在25分鐘內向存於四氫呋喃中之(3-氧代-1,3-二氫-異苯并呋喃-1-基)膦酸二甲基酯(G)及存於四氫呋喃中之2-氟-5-甲醯基苄腈(F)之混合物中逐滴添加三乙基胺,同時將溫度保持低於15℃。在1小時內將反應混合物緩慢升溫至20℃並於真空下濃縮。將白色殘餘物在水中成漿液達30分鐘、過濾、用水、己烷及醚洗滌、並乾燥,獲得2-氟-5-(3-氧代-3H-異苯并呋喃-1-亞基甲基)苄腈(E),其為E及Z異構體之50:50混合物(產率:96%)。
向2-氟-5-(3-氧代-3H-異苯并呋喃-1-亞基甲基)苄腈(E)存於水中之懸浮液中添加氫氧化鈉水溶液並於氮氣下將反應混合物於90℃下加熱達30分鐘。將反應混合物部分冷卻至70℃,添加水合肼並於70℃下攪拌18小時。將反應冷卻至室溫並用2M HCl酸化至pH4。將混合物攪拌10分鐘並過濾。將所得固體用水、己烷、醚、乙酸乙酯洗滌並乾燥,獲得淺粉色粉末狀化合物D(產率:77%)。
亦期望有一種合成化合物D之改良方法。
因此,本發明之第五態樣提供一種合成化合物D之方法,其包括如下步驟:(a)自2-羧基苯甲醛(H)合成(3-氧代-1,3-二氫-2-苯并呋喃-1-基)膦酸二乙酯(G');(b)自(3-氧代-1,3-二氫-2-苯并呋喃-1-基)膦酸二乙酯合成2-氟-5-[(E/Z)-(3-氧代-2-苯并呋喃-1(3H)-亞基)甲基]苄腈(E)。
較佳地,化合物G'在合成中未分離。該方法避免使用在醇溶液中不穩定之亞磷酸二甲酯之鈉鹽(Pelchowicz等人,J.Chem.Soc
,4348-4350(1961))。較佳地,步驟(a)係在亞磷酸二乙酯之鈉鹽於其中穩定之2-甲基四氫呋喃中實施。該鹽可藉由將亞磷酸二乙酯添加至第三戊醇鈉存於2-甲基四氫呋喃中之***液中原位形成。與亞磷酸二乙酯之鈉鹽反應後可與甲烷磺酸反應。
步驟(b)可在2-甲基四氫呋喃中同時添加三乙基胺來實施。
合成化合物D之方法可進一步包括如下步驟:(c)自化合物E藉由與水合肼反應合成2-氟-5-[(4-氧代-3,4-二氫酞嗪-1-基)甲基]苄腈(ED):
及(d)自化合物ED藉由與氫氧化鈉反應合成化合物D。
可藉由使用1.1與1.3當量之間存於四氫呋喃之水合肼、隨後用乙酸中和過量水合肼來達成步驟(c)。
本發明之第六態樣提供化合物ED:
及其在化合物D合成中之用途。
本發明之進一步態樣提供一種1-(環丙基羰基)六氫吡嗪之無機酸鹽、及藉由六氫吡嗪與乙酸反應、隨後添加環丙烷羰醯氯來合成其之方法。
本發明之第七態樣提供一種醫藥組合物,其包括第一態樣之化合物及一醫藥上可接受之載劑或稀釋劑。
本發明之第八態樣提供第一態樣化合物用於治療人體或動物體之方法。
本發明之第九態樣提供本發明第一態樣中所定義之化合物在製備用於抑制PARP活性之藥物中的用途。
本發明之進一步態樣提供本發明第一態樣中所定義之化合物在製備藥物中的用途,該藥物用於治療下列疾病:血管疾病;敗血性休克;缺血性損傷;神經毒性;出血性休克;病毒感染;或藉由抑制PARP活性改善之疾病。
本發明之另一其他態樣提供本發明第一態樣中所定義之化合物在製備藥物中之用途,該藥物在癌症治療中用作輔助藥劑或用於加強利用電離輻射或化學治療劑之腫瘤細胞治療。
本發明之其他態樣提供治療藉由抑制PARP來改善之疾病的方法,其包括投與需要治療之受試者治療有效量之第一態樣所定義、較佳呈醫藥組合物形式的化合物;及治療癌症之方法,其包括投與需要治療之受試者治療有效量之第一態樣所定義、較佳呈醫藥組合物形式的化合物,同時或隨後用電離輻射或化學治療劑治療。
在本發明之其他態樣中,該等化合物可用於製備治療同源重組(HR)依賴性DNA DSB修復活性缺陷之癌症的藥物、或用於治療同源重組(HR)依賴性DNA DSB修復活性缺陷之癌症患者,其包括投與該患者治療有效量之該化合物。
該HR依賴性DNA DSB修復通路經由同源機制修復DNA中之雙鏈斷裂(DSB)以重新形成連續DNA螺旋(K.K.Khanna及S.P.Jackson,Nat.Genet.27(3):247-254(2001))。HR依賴性DNA DSB修復通路之組份包括(但不限於),ATM(NM_000051)、RAD51(NM_002875)、RAD51L1(NM_002877)、RAD51C(NM_002876)、RAD51L3(NM_002878)、DMC1(NM_007068)、XRCC2(NM_005431)、XRCC3(NM_005432)、RAD52(NM_002879)、RAD54L(NM_003579)、RAD54B(NM_012415)、BRCA1(NM_007295)、BRCA2(NM_000059)、RAD50(NM_005732)、MRE11A(NM_005590)及NBS1(NM_002485)。其他參與該HR依賴性DNA DSB修復通路之蛋白質包括諸如EMSY等調節因子(Hughes-Davies等人,Cell
,115
,第523-535頁)。HR組份亦闡述於Wood等人之Science
,291
,1284-1289(2001)中。
HR依賴性DNA DSB修復缺陷之癌症可包含或由一或多個藉助該途徑修復DNA DSB之能力相對於正常細胞降低或消失之癌細胞構成,即,HR依賴性DNA DSB修復通路之活性在該一或多個癌細胞中降低或消失。
在患有HR依賴性DNA DSB修復缺陷之癌症個體的該一或多個癌細胞中一或多個HR依賴性DNA DSB修復通路的組份之活性可能消失。業內已充分識別HR依賴性DNA DSB修復通路之組份(參見例如Wood等人,Science
,291
,1284-1289(2001))且其包括上文所列之組份。
在一些較佳實施例中,該等癌細胞可具有BRCA1及/或BRCA2缺陷表型,即,在癌細胞中BRCA1及/或BRCA2活性降低或消失。具有此表型之癌細胞可能存在BRCA1及/或BRCA2缺陷,即,在癌細胞中BRCA1及/或BRCA2之表現及/或活性可能降低或消失,例如藉助編碼核酸之突變或多態現象、或藉助編碼調節因子之基因(例如編碼BRCA2調節因子之EMSY基因)的擴增、突變或多態現象(Hughes-Davies等人,Cell
,115
,523-535)。
BRCA1及BRCA2為習知之腫瘤抑制基因,其野生型等位基因通常在雜合體攜帶者之腫瘤中丟失(Jasin M.,Oncogene
,21(58)
,8981-93(2002);Tutt等人,Trends Mol Med.
,8(12)
,571-6,(2002))。業內已充分識別BRCA1及/或BRCA2突變與乳癌相關(Radice,P.J.,Exp Clin Cancer Res.
,21(3 Suppl)
,9-12(2002))。亦習知,編碼BRCA2結合因子之EMSY基因的擴增與乳癌及卵巢癌相關。
BRCA1及/或BRCA2突變體攜帶者亦具有升高之卵巢癌、***癌及胰腺癌風險。
在一些較佳實施例中,在BRCA1及/或BRCA2或其調節基因中該個體為一或多種變異(例如突變及多態現象)之雜合體。BRCA1及BRCA2變異檢測已為業內所熟知且描述於,例如歐洲專利第699 754號、歐洲專利第705 903號、Neuhausen,S.L.及Ostrander,E.A.,Genet.Test
,1
,75-83(1992);Chappnis,P.O.及Foulkes,W.D.,Cancer Treat Res
,107
,29-59(2002);Janatova M.等人,Neoplasma
,50(4)
,246-50(2003);Jancarkova,N.,Ceska Gynekol.
,68(1)
,11-6(2003)中。BRCA2結合因子EMSY擴增之確定描述於Hughes-Davies等人之Cell
,115
,523-535中。
與癌症相關之突變及多態現象可在核酸階段藉由檢測變異核酸序列之存在或在蛋白階段藉由檢測變異(即,突變或等位基因變異)多狀之存在來檢測。
本發明提供呈形式A之化合物A作為活性化合物、尤其抑制PARP活性之活性物質。
本文所用術語"活性物質"係指能抑制PARP活性之化合物。一種可方便地用以評價該化合物所提供之PARP抑制之分析闡述於以下實例中。
本發明進一步提供一種在細胞中抑制PARP活性之方法,該方法包括使該細胞接觸有效量之活性化合物,該活性化合物較佳呈醫藥上可接受之組合物形式。此方法可在活體外或活體內實施。
舉例而言,細胞樣品可於活體外生長並使該活性化合物與該等細胞接觸,並觀察該化合物對該等細胞之作用。作為"作用"之實例,可檢測到在一定時間內受影響之DNA修復之量。若發現該活性化合物對該等細胞產生影響,則該化合物可在治療攜帶相同細胞類型之細胞的患者之方法中用作功效的預後或診斷標記物。
本文在治療一病狀之上下文中所用術語"治療"通常係指無論人類還是動物(例如,在獸醫應用中)其中達成某些期望治療效果(例如,抑制該病狀之發展,且包括使發展速度降低、使發展速度停止、改善該病狀及治癒該病狀)之治療及療法。亦包括作為預防措施之治療(即,預防)。
本文所用術語"輔助"係指該活性化合物連同習知治療方法一起使用。該等方法包括用於治療不同癌症類型之藥物的細胞毒性方式及/或電離輻射。具體而言,已知該等活性化合物可加強多種癌症化學治療作用,該等化學治療包括毒劑之拓撲異構酶類型(例如,拓撲替康(topotecan)、伊立替康(irinotecan)、魯比替康(rubitecan))、大多數習用烷基化劑(例如,DTIC、替莫唑胺(temozolamide))及用於治療癌症之基於鉑之藥物(例如卡鉑、順鉑)。
該活性化合物亦可用作抑制PARP之細胞培養添加劑以(例如)使細胞對習知化學治療劑或活體外之電離輻射處理敏感。
該活性化合物亦可作為活體外分析之一部分以(例如)確定一候選宿主是否可能受益於用所述化合物之治療。
該活性化合物或包含該活性化合物之醫藥組合物可藉由任一方便投與途徑投與受試者,無論以全身方式/外周方式還是在期望作用點投與皆可,該作用點包括(但不限於)口(例如藉由攝取);局部(包括例如經皮、鼻內、經眼、經口腔及經舌下);肺部(例如藉由使用例如氣溶膠(例如)通過嘴或鼻吸入或吹入療法);直腸;***;非經腸,例如藉由注射,包括皮下、皮內、肌內、靜脈內、動脈內、心臟內、鞘內、脊柱內、莢膜內、囊下、眼窩內、腹膜腔內、氣管內、表皮下、關節內、蛛網膜下及胸骨內注射;藉由(例如)經皮下或肌內植入儲積物。
該受試者可係真核生物、動物、脊椎動物、哺乳動物、著齒類動物(例如,天竺鼠、倉鼠、大鼠、小鼠)、鼠科動物(例如,小鼠)、犬科動物(例如,狗)、貓科動物(例如,貓)、馬科動物(例如,馬)、靈長類、猿類(例如,猴子或猿)、猴科動物(例如,絨猴、狒狒)、猿類(例如,大猩猩、黑猩猩、猩猩、長臂猿)或人類。
儘管可單獨投與該活性化合物,但其較佳作為一醫藥組合物(例如,調配物)存在,該醫藥組合物包含上文所定義之活性化合物及一或多種醫藥上可接受之載劑、輔助劑、賦形劑、稀釋劑、填充劑、緩衝劑、穩定劑、防腐劑、潤滑劑或其他熟習該項技術者習知的材料及視情況其他治療或預防劑。
因此,本發明進一步提供上文所定義之醫藥組合物及製備一醫藥組合物之方法,該方法包括將上文所定義之活性化合物與一或多種醫藥上可接受之載劑、賦形劑、緩衝劑、輔助劑、穩定劑或其他本文所述之材料混合在一起,以使活性化合物仍呈晶體形式A。
本文所用術語"醫藥上可接受的"係指彼等在合理的藥學判斷範圍內適於與一受試者(例如,人類)之組織接觸使用而無過高毒性、刺激性、過敏性反應或其他問題或併發症並與合理的效益/風險比率相應之化合物、材料、組合物及/或劑型。各載劑、賦形劑等就與該調配物之其他成份相容之意義上而言亦必須係"可接受的"。
適宜載劑、稀釋劑、賦形劑等可在標準醫藥教科書中找到。參見例如"Handbook of Pharmaceutical Additives",第二版(eds.M.Ash及I.Ash),2001(Synapse Information Resources公司,Endicott,New York,USA)、"Remington's Pharmaceutical Sciences",第20版,pub.Lippincott,Williams & Wilkins,2000;及"Handbook of Pharmaceutical Excipients",第二版,1994。
該等調配物可採用方便的單位劑型且可藉由製藥技術中習知之任何方法製備。該等方法包括使該活性化合物與包含一或多種輔助成份之載劑結合之步驟。一般而言,該等調配物可藉由使該活性化合物與液體載劑或微細固體載劑或兩者均勻且充分結合且然後(若必要)使該產物成形來製備。
調配物可呈懸浮液、錠劑、顆粒、粉末、膠囊、藥丸、丸劑或膏糊形式。
適於口服投與(例如,藉由攝取)之調配物可作為下列形式存在:離散單元,例如膠囊、藥丸或錠劑,各皆包含預定量的活性化合物;粉末或顆粒;存於水性液體或非水性液體中之懸浮液;或膏糊。
可視情況使用一或多種輔助成份藉由習知方法(例如,壓縮或模製)製備錠劑。可藉由在一適宜機器中壓縮該呈自由流動形式(例如粉末或顆粒)之活性化合物來製備壓縮錠劑,該活性化合物視情況與一或多種下列成份混合:黏合劑(例如,聚乙烯吡咯啶酮、明膠、***膠、山梨醇、磺著膠、羥丙基甲基纖維素);填充劑或稀釋劑(例如,乳糖、微晶纖維素、磷酸氫鈣);潤滑劑(例如,硬脂酸鎂、滑石粉、二氧化矽);崩解劑(例如,羥乙酸澱粉鈉、經交聯聚乙烯吡咯啶酮、經交聯羧甲基纖維素鈉);表面活性劑或分散劑或潤濕劑(例如,月桂基硫酸鈉);及防腐劑(例如,對-羥基苯甲酸甲酯、對-羥基苯甲酸丙酯、山梨酸)。可藉由在一適宜機器中模製經惰性液體稀釋劑潤濕之粉末狀化合物之混合物來製備模製錠劑。該等錠劑可視情況經塗敷或刻痕且可經調配以便使用(例如)各種比例之羥丙基甲基纖維素提供其中之活性化合物的緩慢或控制釋放以提供期望的釋放性質。錠劑可視情況具有一腸溶衣以在部分內臟而非胃中提供釋放。
膠囊可包括呈懸浮液之活性化合物。
適於局部投與(例如,經皮、鼻內、經眼、頰內及舌下)之調配物可調配成膏糊。
適用於局部投與眼睛之調配物亦包括滴眼劑,其中該活性化合物懸浮於適宜載劑中,尤指用於該活性化合物之水性溶劑。
適用於經鼻投與之調配物(其中該載劑為一固體)包括具有(例如)約20至約500微米粒徑之粗粉末,其以其中藉由(即)藉助鼻腔自一保持靠近鼻子處之粉末容器快速吸入來攝取之方式投與。
適於藉由吸入投與之調配物包括彼等呈加壓包裝之氣溶膠噴霧者,其同時使用諸如二氯二氟甲烷、三氯氟甲烷、二氯-四氟乙烷、二氧化碳或其他適宜氣體等適宜推進劑。
應瞭解,該活性化合物及包含該活性化合物之組合物的適宜劑量可因患者而異。最佳劑量之確定通常涉及治療效益程度與本發明治療之任何風險或有害副作用之平衡。該經選擇之劑量程度應端視各種因素而定,該等因素包括(但不限於)特定化合物之活性、投與途徑、投與時間、該化合物之***速率、治療持續時間、該組合中所用其他藥物、化合物及/或材料、及患者的年齡、性別、重量、狀況、全身健康狀況及先前醫療史。化合物之量及投與途徑最終應由醫師判斷,但通常該劑量在作用點應達到達成期望效果而不會造成實質性傷害或有害副作用之局部濃度。
活體內投與可在整個治療過程中以單劑量連續或間歇(例如,依適宜間隔時間投與分割之劑量)實施。確定最有效投與方法及劑量之方法已為熟習此項技術者所習知且應隨用於治療之調配物、治療之目的、所治療之靶細胞及所治療之受試者而變化。可根據主治醫師所選擇之劑量程度及模式實施單次或多次投與。
一般而言,該活性化合物之適宜劑量介於約10毫克至約600毫克/平方米身體面積受試者體重/天之間。
起始材料(D)藉由WO 2004/080976所揭示之方法合成。
方法 製備型HPLC
用一Waters質量指導之純化系統純化樣品,該系統使用Waters 600 LC幫浦、Waters Xterra C18管柱(5微米,19毫米×50毫米)及Micromass ZQ質譜儀,以陽離子電噴射離子化模式操作。流動相A(0.1%存於水中之甲酸)及B(0.1%存於乙腈中之甲酸)以梯度使用;在7分鐘內自5% B至100%,保持3分鐘,流速為20毫升/分鐘。
分析型HPLC-MS
分析型HPLC係使用Spectra System P4000幫浦及Jones Genesis C18管柱(4微米,50毫米×4.6毫米)來實施。流動相A(0.1%存於水中之甲酸)及B(乙腈)使用5% B保持1分鐘、5分鐘後升至98% B之梯度,以2毫升/分鐘之流速保持3分鐘。藉由TSP UV 6000LP檢測器於254奈米UV及量程210-600奈米PDA檢測。質譜儀係以陽離子電噴射模式操作之Finnigan LCQ。
NMR 1
H NMR光譜係在300 MHz下使用Bruker DPX 300光譜儀進行記錄。化學位移係根據相對於四甲基矽烷內標之δ標度以百萬分率(ppm)報告。除非另有說明否則所有樣品皆溶於DMSO-d6
。
(a)4-[2-氟-5-(4-氧代-3,4-二氫-酞嗪-1-基甲基)-苯甲醯基]-六氫吡嗪-1-甲酸第三-丁基酯(C)
於室溫下在氮氣下向起始材料D(850克)存於二甲基乙醯胺(DMA)(3561毫升)中之攪拌溶液中一次性添加HBTU(六氟磷酸2-(1H-苯并***-1-基)-1,1,3,3-四甲基脲鎓)(1402克)。然後添加Hnig's鹼(iPr2
Net,1096毫升),同時將溫度保持在15℃至25℃之間,隨後添加1-Boc-六氫吡嗪(637克)存於DMA(1428毫升)中之溶液,同時將溫度保持在15℃至25℃之間。
於室溫下將溶液攪拌2小時並取樣用於確定是否完成(HPLC)。完成後,將溶液添加至劇烈攪拌的水(17085毫升)中,同時將溫度保持在15℃至25℃之間並濾出固體、用水(2×7131毫升)、己烷(2×7131毫升)及甲基第三-丁基醚(MTBE)(2×3561毫升)洗滌。然後將固體乾燥過夜,隨後取樣用於水含量及化學純度分析。
然後重複該反應,參見下表:
a.大於100%產率係由於非代表性取樣(b)4-[4-氟-3-(六氫吡嗪-1-羰基)-苄基]-2H-酞嗪-1-酮(B)
在室溫於氮氣下向工業甲基化乙醇(IMS)(2200毫升)及濃HCl(4400毫升)之攪拌溶液中分次添加化合物C(2780.2克),藉由添加速率來控制起泡。然後在15℃至25℃下將溶液攪拌30分鐘並取樣用於確定是否完成(HPLC)。
完成後蒸發該溶液以移除任何IMS並用CH2
Cl2
(2×3500毫升)萃取含水物質,然後使用濃氨水將pH值調至>8。然後用水(10000毫升)稀釋所得漿液並用CH2
Cl2
(4×3500毫升)萃取、用水(2×2000毫升)洗滌、經MgSO4
(250克)乾燥並蒸發。然後將粗產物在CH2
Cl2
(3500毫升)中變成漿液並添加至MTBE(5000毫升)中。過濾所得懸浮液並於50℃乾燥過夜,獲得611.0克(58.5%產率)純度為94.12%之材料。
(c)4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮(A)
在氮氣下向化合物B(1290克)存於CH2
Cl2
(15480毫升)中之攪拌懸浮液中逐滴添加三乙基胺(470毫升)及環丙烷羰醯氯(306毫升)存於CH2
Cl2
(1290毫升)中之預混合溶液,同時將溫度保持低於20℃。然後在10-15℃下將該溶液攪拌15分鐘並取樣用於確定是否完成。發現反應混合物僅含1.18%起始材料B並因此認為反應已完成且隨後實施分批處理。
用水(7595毫升)、5%檸檬酸溶液(7595毫升)、5%碳酸鈉溶液(7595毫升)及水(7595毫升)洗滌該反應混合物。然後經硫酸鎂(500克)乾燥該有機層。
然後分離包含CH2
Cl2
之產物層,藉助Celite過濾並裝填於25公升容器中。然後於常壓下蒸餾出CH2
Cl2
(8445毫升)並添加乙醇(10000毫升)。然後繼續蒸餾,同時所有4000毫升被移除之餾出物用乙醇(4000毫升)代替,直至頭部溫度達73.7℃為止。然後反應體積減少(至7730毫升),此時頭部溫度達78.9℃並使該溶液冷卻至8℃過夜。然後過濾出固體,用乙醇(1290毫升)洗滌並於70℃乾燥過夜。
產率=1377.3克(90%)。HPLC純度(99.34%[面積%])。藉由GC包含4.93%乙醇及0.45% CH2
Cl2
。
(d)化合物A之水處理
將如藉由實例1之方法所製造化合物A(1377.0克)存於水中的懸浮液加熱回流達4小時,冷卻至室溫並過濾。用水(2754毫升)洗滌固體並於70℃乾燥過夜。
產率=1274.8克(92.6%)。HPLC純度(99.49%[面積%])。藉由GC包含0.01%乙醇及0.01% CH2
Cl2
。
水處理後化合物A之1
H NMR光譜(DMSO-d6)顯示於圖1中。
水處理後化合物A之粉末XRD圖案顯示於圖2中,該圖顯示該化合物呈形式A。
方法(亦用於實例3及4) NMR 1
H-NMR光譜係在400 MHz下使用Bruker DPX 400光譜儀進行記錄。化學位移係根據相對於四甲基矽烷內標之δ標度以百萬分率(ppm)報告。除非另有說明,否則所有樣品皆溶解於DMSO-d6
中。
質譜
質譜係於Agilent XCT離子陷阱質譜儀上使用用於結構確定之串列質譜法(MS/MS)記錄。該儀器以陽離子電噴射模式操作。
(a)4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮(化合物A)
在氮氣下攪拌的同時將2-氟-5-[(4-氧代-3,4-二氫酞嗪-1-基)甲基]苯甲酸(D)(15.23克,51.07毫莫耳)懸浮於乙腈(96毫升)中。添加二異丙基乙基胺(19.6毫升,112.3毫莫耳),隨後添加1-環丙基羰基六氫吡嗪(I)(9.45克,61.28毫莫耳)及乙腈(1毫升)。將反應混合物冷卻至18℃。然後在30分鐘內添加六氟磷酸O-苯并***-1-基-四甲基脲鎓(25.18克,66.39毫莫耳)並於室溫下將該反應混合物攪拌2小時。將該反應混合物冷卻至3℃並維持在此溫度達1小時,然後過濾。用冷(3℃)乙腈(20毫升)洗滌濾餅,然後於真空下高達40℃之溫度下將其乾燥,獲得淺黃色固體狀標題化合物(20.21克)。
質譜
:MH+ 4351H NMR(400 MHz,DMSO-d6)δ
:0.70(m,4H)、1.88(br s,1H)、3.20(br s,2H)、3.56(m,6H)、4.31(s,2H)、7.17(t,1H)、7.34(dd,1H)、7.41(m,1H)、7.77(dt,1H)、7.83(dt,1H)、7.92(d,1H)、8.25(dd,1H)、12.53(s,1H)。
(a)1-(環丙基羰基)六氫吡嗪HCl鹽(I')
在15分鐘內於氮氣下邊攪拌邊用六氫吡嗪(50.00克,0.581莫耳)逐份處理乙酸(700毫升)。將該反應混合物加熱至40℃並維持在此溫度直至獲得一完全溶液。在15分鐘內添加環丙烷羰醯氯(59.2毫升,0.638莫耳)。將該反應混合物在室溫下攪拌過夜。過濾該反應混合物並於降低之壓力下蒸餾濾液直至收集到約430毫升餾出物。將甲苯(550毫升)裝填至該反應混合物中並繼續降壓蒸餾直至進一步收集到400毫升餾出物。進一步裝填甲苯(550毫升)並繼續降壓蒸餾直至收集到350毫升餾出物。用甲苯(200毫升)稀釋所得漿液並將其攪拌過夜。進一步添加甲苯(500毫升)以使漿液流動。過濾該漿液、用甲苯(100毫升)洗滌並在真空下於40℃乾燥,獲得灰白色固體狀標題化合物(86.78克)。
質譜:MH+ 1551H NMR(400 MHz,D 2 O)δ
:0.92(m,4H)、1.98(m,1H)、3.29(m,2H)、3.38(m,2H)、3.84(m,2H)、4.08(m,2H)。
(b)化合物A
在氮氣下攪拌的同時將2-氟-5-[(4-氧代-3,4-二氫酞嗪-1-基)甲基]苯甲酸(D)(0.95克,3.19毫莫耳)懸浮於乙腈(4毫升)中。添加六氟磷酸2-(1H-苯并***-1-基)-1,1,3,3-四甲基脲鎓(HBTU)(1.45克,3.83毫莫耳),然後添加1-環丙基羰基六氫吡嗪HCl鹽(I')(0.73克,3.83毫莫耳)。在3分鐘內添加二異丙基乙基胺(1.39毫升,7.98毫莫耳)並在室溫下將該反應混合物攪拌過夜。將該反應混合物冷卻至5℃並維持在此溫度達1小時,然後過濾。用冷(3℃)乙腈(2毫升)洗滌濾餅,然後在真空下於高達40℃之溫度下將其乾燥以獲得淺黃色固體狀標題化合物(0.93克)。
(c)化合物A自含水甲醇之再結晶
將源自步驟(b)之化合物A(9.40克,21.64毫莫耳)懸浮於水(100毫升)及甲醇(120毫升)之混合物中。邊攪拌邊將該懸浮液加熱至回流。然後將所產生之混濁溶液冷卻至60℃並藉助harborlite墊過濾。用水(5毫升)與甲醇(5毫升)之混合物洗滌濾墊。於常壓下蒸餾該濾液直至收集到115毫升餾出物。然後停止蒸餾並使所產生之懸浮液冷卻至室溫。將該所得懸浮液攪拌約18小時,然後過濾。用水(20毫升)洗滌濾餅,然後在真空下於高達60℃之溫度下將其乾燥以獲得白色固體狀呈形式A的標題化合物(8.67克)。
質譜
:MH+ 4351H NMR(400 MHz,DMSO-d6)δ
:0.70(m,4H)、1.88(br s,1H)、3.20(br s,2H)、3.56(m,6H)、4.31(s,2H)、7.17(t,1H)、7.34(dd,1H)、7.41(m,1H)、7.77(dt,1H)、7.83(dt,1H)、7.92(d,1H)、8.25(dd,1H)、12.53(s,1H)。
(d)化合物A自含水乙醇之再結晶
將源自步驟(b)之化合物A(9.40克,21.64毫莫耳)懸浮於水(100毫升)與乙醇(50毫升)之混合物中。邊攪拌邊將懸浮液加熱至回流。然後將所產生之混濁溶液冷卻至60℃並藉助harborlite墊過濾。用水(5毫升)與乙醇(5毫升)之混合物洗滌濾墊。在常壓下蒸餾濾液直至收集到53毫升餾出物。然後停止蒸餾並使所產生之懸浮液冷卻至室溫。將所得懸浮液攪拌約18小時,然後過濾。用水(20毫升)洗滌濾餅,然後在真空中於60℃下將其乾燥以獲得白色固體狀呈形式A之標題化合物(8.74克)。
質譜
:MH+ 4351H NMR(400 MHz,DMSO-d6)δ
:0.70(m,4H)、1.88(br s,1H)、3.20(br s,2H)、3.56(m,6H)、4.31(s,2H)、7.17(t,1H)、7.34(dd,1H)、7.41(m,1H)、7.77(dt,1H)、7.83(dt,1H)、7.92(d,1H)、8.25(dd,1H)、12.53(s,1H)。
(a)2-氟-5-[(E/Z)-(3-氧代-2-苯并呋喃-1(3H)-亞基)甲基]苄腈(E)
在氮氣氣氛下將第三戊醇鈉(99.00克,0.854莫耳)及2-甲基四氫呋喃(960毫升)冷卻至2℃。逐滴添加亞磷酸二乙酯(110毫升,0.855莫耳)並維持溫度<5℃。添加2-甲基四氫呋喃(40毫升)進行線上洗滌。於2℃下將反應攪拌1小時40分鐘。添加2-羧基苯甲醛(H)(80克,0.533莫耳)存於2-甲基四氫呋喃(200毫升)中之溶液並在整個添加過程維持溫度<7℃。添加2-甲基四氫呋喃(40毫升)進行線上洗滌。將該反應混合物升溫至20℃並於20℃下維持20分鐘。在1小時10分鐘內添加甲烷磺酸(66毫升,1.01莫耳),然後添加2-甲基四氫呋喃(40毫升)。在20℃下將該反應混合物攪拌過夜。添加甲烷磺酸(7毫升,0.101莫耳),隨後添加2-甲基四氫呋喃(7毫升)並於20℃下將反應混合物再攪拌4小時。於室溫下添加水(400毫升)並於室溫下將所得兩相混合物攪拌20分鐘。移除下部水層並將碳酸氫鉀(53.50克,0.534莫耳)存於水(400毫升)中之溶液添加至有機層中。於室溫下將該雙相混合物攪拌20分鐘且隨後移除下部水溶液。保留有機部分((3-氧代1,3-二氫-2-苯并呋喃-1-基)膦酸二乙酯溶液)。將2-氟-5-甲醯基苄腈(64克,0.429莫耳)添加至有機部分中並於20℃下攪拌該混合物。逐滴添加三乙基胺(66毫升,0.473莫耳),隨後添加2-甲基四氫呋喃(7毫升)。然後於20℃下將該反應混合物攪拌過夜,然後冷卻至5℃,過濾,用工業甲基化乙醇(480毫升)洗滌並隨後在真空中於高達40℃之溫度下乾燥,獲得標題化合物(91.2克)。
質譜
:MH+ 2661H NMR(400 MHz,DMSO-d6)δ
:6.89(s,1H,主要異構體)、6.94(s,1H,次要異構體)、7.40(dd,1H,次要異構體)、7.58(t,1H,兩種異構體)、7.70(t,1H,兩種異構體)、7.89(t,1H,兩種異構體)、7.95(d,1H,兩種異構體)、8.05(d,1H,兩種異構體)、8.15(m,2H,兩種異構體)。
(b)2-氟-5-[(4-氧代-3,4-二氫酞嗪-1-基)甲基]苄腈(ED)
在氮氣氣氛下,於室溫下將2-氟-5-[(E/Z)-(3-氧代-2-苯并呋喃-1(3H)-亞基)甲基]苄腈(E)(20克,75.40毫莫耳)及四氫呋喃(200毫升)攪拌30分鐘。添加單水合肼(4.40毫升,90.53毫莫耳),隨後添加四氫呋喃(4毫升)用以線洗。於室溫下將該反應混合物攪拌1小時45分鐘。添加乙酸(1.10毫升,19.20毫莫耳)並將反應混合物升溫至60℃。將反應混合物保持在60℃過夜。將反應混合物冷卻至50℃並逐滴添加水(200毫升)。在整個添加過程中將溫度維持在45℃。將反應混合物冷卻至20℃,過濾,用水(30毫升)及四氫呋喃(30毫升)之混合物洗滌,並隨後在真空中於高達40℃下將其乾燥以獲得標題化合物(18.7克)。
質譜
:MH+ 2801H NMR(400 MHz,DMSO-d6)δ
:4.38(s,2H)、7.46(t,1H)、7.72(m,1H)、7.85(dt,1H)、7.92(m,2H)、7.99(d,1H)、8.27(dd,1H)、12.57(s,1H)。
(c)2-氟-5-[(4-氧代-3,4-二氫酞嗪-1-基)甲基]苯甲酸(D)
於20℃下攪拌2-氟-5-[(4-氧代-3,4-二氫酞嗪-1-基)甲基]苄腈(ED)(9.60克,34.37毫莫耳)及水(40毫升)。添加2 M氫氧化鈉(36毫升,72.00毫莫耳),將反應混合物升溫至90℃並維持此溫度過夜。將反應混合物冷卻至室溫並過濾。用水(10毫升)洗滌濾墊並於60℃下在40分鐘內將經合併之濾液添加至2M HCl(56毫升,112.00毫莫耳)中。將所得懸浮液冷卻至50℃並過濾,用水(57毫升)洗滌並在真空中於高達60℃下將其乾燥以獲得白色固體狀標題化合物(9.72克)。
質譜
:MH+ 2991H NMR(400 MHz,DMSO-d6)δ
:4.36(s,2H)、7.24(dd,1H)、7.59(m,1H)、7.84(dt,2H)、7.90(dt,1H)、7.98(d,1H)、8.27(dd,1H)、12.59(s,1H)、13.22(br s,1H)。
將4-(3-{[4-(環丙基羰基)六氫吡嗪-1-基]羰基}-4-氟苄基)酞嗪-1(2H)-酮(化合物A)(20.00克,44.66毫莫耳)懸浮於水(50毫升)與乙醇(150毫升)之混合物中。邊攪拌邊將該懸浮液加熱至回流。然後將所產生之溶液冷卻至70℃並過濾。用水(8毫升)與乙醇(22毫升)之混合物洗滌濾墊。
邊攪拌邊將濾液冷卻至45℃。添加呈形式A之4-(3-{[4-(環丙基羰基)六氫吡嗪-1-基]羰基}-4-氟苄基)酞嗪-1(2H)-酮(化合物A)(0.08克)以為混合物種晶種。在2.5小時內將所得懸浮液冷卻至20℃並於此溫度下再攪拌16小時以產生結晶。在5小時內添加水(200毫升)並將溫度維持在20℃。在添加結束後將懸浮液維持在20℃達2小時。
過濾該懸浮液並用乙醇(24毫升)與水(56毫升)之混合物洗滌濾餅。取出經分離之固體並在真空中於40-60℃下將其乾燥,獲得灰白色固體狀標題化合物(形式A)(18.1克)。
獲得圖3-5之方法粉末XRD-圖3(呈形式A之化合物A)
粉末X-射線繞射係使用Bruker D5000繞射儀(X-射線之波長為1.5418Cu源,電壓40 kV,燈絲發射40 mA)記錄。使用0.02°步寬及4秒鐘時間計數自2-40° 2θ掃描樣品。
粉末XRD-圖4(溶合形式之化合物A)
溶劑合物種類之粉末X-射線繞射係使用一裝配有彎曲位置敏感檢測器(範圍120° 2θ)之Inel XRG-3000繞射儀(X-射線之波長為1.5418Cu源、電壓40 kV、燈絲級發射30 mA)記錄。使用0.03°步寬自2.5-40° 2θ掃描樣品,通常總收集時間為300秒鐘。
差示掃描量熱法(DSC)-圖5
使用一具有TSO801RO自動化系統之Mettler DSC820E記錄DSC。通常將少於5克之材料包含於40微升配有刺破蓋子的鋁盤中,以10℃/分鐘之恆定加熱速率在25℃至325℃溫度範圍內加熱。以100毫升/分鐘之流速使用氮氣吹掃氣。
抑制作用
使用下列分析來測定IC50
值以便評價該活性化合物之抑制作用。
在96孔FlashPlates(商標名)(NEN,UK)中用Z-緩衝液(25 mM Hepes(Sigma);12.5 mM MgCl2
(Sigma);50 mM KCl(Sigma);1 mM DTT(Sigma);10%甘油(Sigma);0.001% NP-40(Sigma);pH 7.4)培養自Hela細胞核提取物分離之哺乳動物PARP並添加不同濃度之該等抑制劑。所有化合物皆稀釋於DMSO中並提供介於10與0.01 μM間之最終分析濃度,同時DMSO之最終濃度為1%/孔。每孔之總分析體積為40微升。
於30℃下培養10分鐘後,藉由添加10微升包含NAD(5 μM)、3
H-NAD及30 mer雙鏈DNA寡聚物之反應混合物來開始反應。指定之陽性及陰性反應孔與化合物孔(未知)一起處理以便計算%酵素活性。然後將該等板振盪2分鐘並於30℃下培育45分鐘。
培育後,藉由添加50微升30%乙酸至各孔中來淬滅反應。然後將該等板於室溫下振盪1小時。
將該等板轉移至TopCount NXT(商標名)(Packard,UK)用於閃爍計數。所記錄之值為各孔計數30秒鐘後之計數/分鐘(cpm)。
然後使用以下等式計算該化合物之%酵素活性:
計算IC50
值(50%酵素活性受到抑制之濃度),該值係在一系列不同濃度內(通常自10 μM低至0.001 μM)測定。該等IC50
用作比較值以確定化合物效力的增加。
化合物A具有約5 nM之IC50
。
增強係數
活性化合物之增強係數(PF50
)係計算成對照細胞生長之IC50
除以添加PARP抑制劑之細胞生長之IC50
的比率。對照及經化合物處理細胞的生長抑制曲線皆在烷基化試劑甲烷磺酸甲酯(MMS)存在下測得。測試化合物以0.2微莫耳之固定濃度使用。MMS之濃度介於0至10微克/毫升之間。
使用磺醯羅丹明B(sulforhodamine B)(SRB)分析評價細胞生長(Skehan,P.等人,(1990)New colorimetric cytotoxicity assay for anticancer-drug screening.J.Natl.CancerInst.82,1107-1112.)。將2,000個HeLa細胞以100微升之體積接種於平底96孔微量滴定板之各孔中並於37℃培育6小時。用單獨的培養基或包含終濃度為0.5、1或5 μM PARP抑制劑之培養基替換細胞培養基。使細胞再生長1小時,然後將一系列濃度(通常為0、1、2、3、5、7及10微克/毫升)之MMS添加至未處理細胞或經PARP抑制劑處理之細胞。使用經由PARP抑制劑單獨處理之細胞來評價由PARP抑制劑引起之生長抑制。
將細胞再放置16小時,然後替換培養基並於37℃下使細胞再生長72小時。然後移除培養基並隨後用100微升冰冷的10%(w/v)三氯乙酸固定細胞。將該等板於4℃培育20分鐘並隨後用水洗滌4次。然後用100微升溶於0.4%(w/v)存於1%乙酸中之SRB對各孔之細胞實施染色達20分鐘,然後用1%乙酸洗滌4次。然後將板在室溫下乾燥2小時。藉由添加100微升10 mM Tris鹼至各孔中來溶解經染色細胞之染料。輕輕搖動板並將其於室溫下放置30分鐘,然後在Microquant微量滴定板讀取器上於564 nM下量測光密度。
化合物A在200 nM具有至少20之PF50
。
圖1顯示化合物A水處理後之NMR(實例1);圖2顯示呈形式A之化合物A水處理後的粉末XRD圖案(實例1);圖3顯示呈形式A之化合物A的代表性粉末XRD圖案;圖4顯示呈溶合形式之化合物A的代表性粉末XRD圖案;圖5顯示呈形式A之化合物A的代表性DSC痕跡,其係藉由以10℃/分鐘自25℃加熱至325℃獲得。
(無元件符號說明)
Claims (20)
- 一種4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮,其呈晶體形式A,在粉末XRD中具有下列特徵峰:
- 如請求項1之化合物,其在粉末XRD中具有下列特徵峰:
- 如請求項1或2之化合物,其在DSC中以10℃/分鐘自25℃ 加熱至325℃時在210.1℃±1℃開始熔化。
- 一種獲得呈晶體形式A之4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮(化合物A)之方法,其包括如下步驟:(i)自溶劑中結晶析出4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮;(ii)若初始溶劑不為乙醇,則用乙醇處理該晶體化合物A;(iii)用水處理該晶體化合物A以移除所捕獲乙醇;(iv)乾燥所得產物。
- 一種獲得呈晶體形式A之4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮(化合物A)之方法,其包括如下步驟:(i)自溶劑中結晶析出4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮;(ii)若呈晶體形式之化合物A合成法所用初始溶劑不為水與C1-2 醇之混合物,則將該化合物與水與C1-2 醇之混合物一起加熱;(iii)於常壓下蒸餾該混合物;及(iv)乾燥所得產物。
- 一種獲得呈晶體形式A之4-[3-(4-環丙烷羰基-六氫吡嗪-1-羰基)-4-氟-苄基]-2H-酞嗪-1-酮(化合物A)之方法,其包括如下步驟:(i)將化合物A懸浮於作為溶劑之水與C1-2 醇的混合物 中;(ii)加熱該懸浮液至回流;(iii)冷卻該溶液並用接種呈形式A之化合物A晶種;(iv)乾燥所得產物。
- 一種醫藥組合物,其包括如請求項1至3中任一項之化合物及一醫藥上可接受之載劑或稀釋劑。
- 如請求項1或2之化合物,其用於治療人體或動物體之方法中。
- 如請求項1或2之化合物,其用於在人體或動物體治療中抑制PARP之方法中。
- 一種如請求項1至3中任一項之化合物在製備藥物中之的用途,該藥物用於抑制PARP活性。
- 一種如請求項1至3中任一項之化合物在製備藥物中的用途,該藥物用於治療下列疾病:血管疾病;敗血性休克;缺血性損傷;神經毒性;出血性休克;病毒感染;或可藉由抑制PARP活性來改善之疾病。
- 一種如請求項1至3中任一項之化合物在製備藥物中之用途,該藥物用於在癌症治療中用作輔助藥劑或用於加強利用電離輻射或化學治療劑之腫瘤細胞治療。
- 一種如請求項1至3中任一項之化合物在製造用於治療個體中癌症的藥物中之用途,其中該癌症存在HR依賴性DNA DSB修復通路缺陷。
- 如請求項13之用途,其中該癌症包含一或多個相對於正常細胞已降低或消失由HR修復DNA DSB的能力之癌細 胞。
- 如請求項14之用途,其中該等癌細胞具有BRCA1或BRCA2缺陷表型。
- 如請求項15之用途,其中該等癌細胞存在BRCA1或BRCA2缺陷。
- 如請求項13至16中任一項之用途,其中該個體係編碼HR依賴性DNA DSB修復通路之組份的基因突變之雜合體。
- 如請求項17之用途,其中該個體係BRCA1及/或BRCA2突變之雜合體。
- 如請求項13至16中任一項之用途,其中該癌症係乳癌、卵巢癌、胰腺癌或***癌。
- 如請求項13至16中任一項之用途,其中該治療進一步包括投與電離輻射或化學治療劑。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82969406P | 2006-10-17 | 2006-10-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200825066A TW200825066A (en) | 2008-06-16 |
TWI404716B true TWI404716B (zh) | 2013-08-11 |
Family
ID=38952365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW096138353A TWI404716B (zh) | 2006-10-17 | 2007-10-12 | 酞嗪酮(phthalazinone)衍生物 |
Country Status (35)
Country | Link |
---|---|
US (2) | US7692006B2 (zh) |
EP (3) | EP2064189B1 (zh) |
JP (3) | JP5248513B2 (zh) |
KR (2) | KR20140011425A (zh) |
CN (3) | CN102627611A (zh) |
AR (1) | AR063320A1 (zh) |
AT (1) | ATE528296T1 (zh) |
AU (1) | AU2007311766B2 (zh) |
BR (1) | BRPI0717125B8 (zh) |
CA (2) | CA2875147C (zh) |
CL (1) | CL2007002967A1 (zh) |
CO (1) | CO6210728A2 (zh) |
CY (1) | CY1112345T1 (zh) |
DK (1) | DK2064189T3 (zh) |
ES (2) | ES2587129T3 (zh) |
HK (2) | HK1126483A1 (zh) |
HR (1) | HRP20120007T1 (zh) |
IL (2) | IL197420A (zh) |
ME (1) | ME01987B (zh) |
MX (1) | MX2009004103A (zh) |
MY (2) | MY162829A (zh) |
NO (2) | NO341963B1 (zh) |
NZ (1) | NZ575627A (zh) |
PE (1) | PE20081175A1 (zh) |
PL (1) | PL2064189T3 (zh) |
PT (1) | PT2064189E (zh) |
RS (1) | RS52112B (zh) |
RU (1) | RU2465270C3 (zh) |
SA (2) | SA07280551B1 (zh) |
SG (2) | SG10201408404XA (zh) |
SI (1) | SI2064189T1 (zh) |
TW (1) | TWI404716B (zh) |
UA (1) | UA97494C2 (zh) |
UY (1) | UY30639A1 (zh) |
WO (1) | WO2008047082A2 (zh) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151102B2 (en) * | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
GB0428111D0 (en) * | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
WO2007144652A2 (en) * | 2006-06-15 | 2007-12-21 | Kudos Pharmaceuticals Limited | Parp inhibitors |
US20090209520A1 (en) * | 2006-06-15 | 2009-08-20 | Kudos Pharmaceuticals Limited | 2 -oxybenzamide derivatives as parp inhibitors |
US20090281086A1 (en) * | 2006-06-15 | 2009-11-12 | Kudos Pharmaceuticals Limited | 2 -oxyheteroarylamide derivatives as parp inhibitors |
UY30639A1 (es) * | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
BRPI0722070A2 (pt) * | 2006-12-28 | 2014-04-08 | Abbott Lab | Inibidores de poli(adp-ribose)polimerase |
US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
TW200900396A (en) * | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
WO2009050469A1 (en) * | 2007-10-17 | 2009-04-23 | Kudos Pharmaceuticals Limited | 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one |
ME02640B (me) * | 2008-10-07 | 2017-06-20 | Kudos Pharm Ltd | Farmaceutske formulacije 514 |
UY32790A (es) * | 2009-07-15 | 2011-02-28 | Astrazeneca Ab | Compuesto de ftalazinona |
WO2012014221A1 (en) | 2010-07-27 | 2012-02-02 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
CN102485721B (zh) * | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
EP2804602A4 (en) | 2012-01-20 | 2016-08-10 | Dennis Brown | USE OF SUBSTITUTED HEXITOLS WITH DIANHYDROGALACTITOL AND ANALOGUE FOR THE TREATMENT OF NEOPLASTIC DISEASES AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTFORME AND MEDULLOBLASTOMA |
HUE030613T2 (en) | 2012-12-31 | 2017-05-29 | Cadila Healthcare Ltd | Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 |
EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
AU2015240465B2 (en) | 2014-04-04 | 2020-02-27 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
JP6936007B2 (ja) | 2014-06-17 | 2021-09-15 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Chk1阻害剤とatr阻害剤との組み合わせを使用してがんを処置する方法 |
CN105777651A (zh) * | 2015-01-13 | 2016-07-20 | 江苏豪森药业集团有限公司 | 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途 |
CN105985294B (zh) * | 2015-02-11 | 2020-12-25 | 四川科伦药物研究院有限公司 | 一种奥拉帕尼的制备方法 |
CN105753789B (zh) * | 2015-04-17 | 2018-09-25 | 苏州晶云药物科技有限公司 | 奥拉帕尼与尿素的共晶及其制备方法 |
CN106146492A (zh) * | 2015-04-17 | 2016-11-23 | 上海汇伦生命科技有限公司 | 杂环并咪唑类化合物、其药物组合物及其制备方法和用途 |
WO2016187620A2 (en) | 2015-05-21 | 2016-11-24 | The Regents Of The University Of California | Anti-cancer compounds |
CN105439961A (zh) * | 2015-06-12 | 2016-03-30 | 苏州晶云药物科技有限公司 | 奥拉帕尼的晶型i及其制备方法 |
CN105175370A (zh) * | 2015-07-27 | 2015-12-23 | 安徽万邦医药科技有限公司 | 一种2-氟-5-[(3-氧代-1(3h)-异苯并呋喃亚基)甲基]苯腈的合成方法 |
MX2018003657A (es) | 2015-09-30 | 2018-04-30 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr). |
CN105254572A (zh) * | 2015-11-09 | 2016-01-20 | 北京科莱博医药开发有限责任公司 | 一种奥拉帕尼的晶型及其制备方法和应用 |
CN106699672B (zh) * | 2015-11-16 | 2019-10-29 | 上海博邦医药科技有限公司 | 一种奥拉帕尼无定型物及其制备方法 |
ITUB20159206A1 (it) | 2015-12-22 | 2017-06-22 | Olon Spa | Forme cristalline e amorfe di olaparib |
US20170204067A1 (en) * | 2016-01-14 | 2017-07-20 | Scinopharm Taiwan, Ltd. | Crystalline forms of olaparib and manufacturing processes therefor |
CZ201682A3 (cs) | 2016-02-15 | 2017-08-23 | Zentiva, K.S. | Solvatované krystalické formy olaparibu, jejich příprava a použití |
CN105503739B (zh) * | 2016-02-24 | 2018-09-11 | 合肥启旸生物科技有限公司 | 一种奥拉帕尼的制备方法 |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
WO2017153958A1 (en) * | 2016-03-11 | 2017-09-14 | Lupin Limited | Novel polymorphic forms and amorphous form of olaparib |
CN107304187B (zh) * | 2016-04-25 | 2021-07-09 | 杭州容立医药科技有限公司 | 一种奥拉帕尼的重结晶方法 |
CN107304186B (zh) * | 2016-04-25 | 2021-08-27 | 杭州容立医药科技有限公司 | 一种奥拉帕尼的精制方法 |
WO2017191562A1 (en) * | 2016-05-04 | 2017-11-09 | Alembic Pharmaceuticals Limited | Process for the preparation of olaparib and polymorphs thereof |
SG11201811393WA (en) | 2016-06-24 | 2019-01-30 | Univ California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
EP3263529B1 (en) | 2016-06-27 | 2019-11-06 | Xylem Europe GmbH | Quartz sleeve support for an uv-lamp |
CZ2016391A3 (cs) | 2016-06-29 | 2018-01-10 | Zentiva, K.S. | Farmaceutická formulace olaparibu |
EP3504196A4 (en) * | 2016-08-24 | 2020-01-22 | Scinopharm Taiwan, Ltd. | PROCESSES FOR THE PREPARATION OF OLAPARIB |
WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
CN107098862A (zh) * | 2017-06-05 | 2017-08-29 | 山东裕欣药业有限公司 | 一种奥拉帕尼二水合物及其制备方法 |
CN107325055A (zh) * | 2017-08-14 | 2017-11-07 | 山东裕欣药业有限公司 | 一种奥拉帕尼化合物的合成方法 |
MY197303A (en) * | 2017-08-24 | 2023-06-12 | Jiangsu Hengrui Medicine Co | Crystal form of parp-1 inhibitor and preparation method therefor |
CN108101852A (zh) * | 2017-12-27 | 2018-06-01 | 山东裕欣药业有限公司 | 一种奥拉帕尼的制备方法 |
WO2019133864A1 (en) | 2017-12-29 | 2019-07-04 | Accutar Biotechnology | DUAL INHIBITORS OF PARP1 and CDK |
PE20211305A1 (es) | 2018-01-05 | 2021-07-20 | Cybrexa 1 Inc | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas |
CA3031777A1 (en) | 2018-01-31 | 2019-07-31 | Apotex Inc. | Crystalline form of olaparib |
CN110204530B (zh) * | 2018-02-28 | 2020-05-08 | 新发药业有限公司 | 一种瓦他拉尼的制备方法 |
CN108558773A (zh) * | 2018-05-17 | 2018-09-21 | 苏州莱克施德药业有限公司 | 一种奥拉帕尼药物中间体的制备方法 |
CN109535082A (zh) * | 2018-12-24 | 2019-03-29 | 合肥创新医药技术有限公司 | 一种奥拉帕尼的制备方法 |
US10703728B1 (en) * | 2019-06-18 | 2020-07-07 | Scinopharm Taiwan, Ltd. | Crystalline form of olaparib and a process for preparing the same |
CN114341162A (zh) | 2019-07-10 | 2022-04-12 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
KR20220051332A (ko) | 2019-07-10 | 2022-04-26 | 싸이브렉사 3, 인크. | 치료제로서의 미세소관 표적화제의 펩티드 접합체 |
WO2021044437A1 (en) * | 2019-09-04 | 2021-03-11 | Cipla Limited | Olaparib co-crystals and process of preparation thereof |
CN110563703B (zh) * | 2019-09-18 | 2021-04-09 | 浙江省医学科学院 | 基于crbn配体诱导parp-1降解的化合物及制备方法和应用 |
WO2021133886A1 (en) | 2019-12-23 | 2021-07-01 | Accutar Biotechnology | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer |
CN111116514B (zh) * | 2020-01-10 | 2024-03-19 | 广州科锐特生物科技有限公司 | 一种1-环丙甲酰基哌嗪盐酸盐的制备方法 |
CN115485271A (zh) | 2020-04-28 | 2022-12-16 | 理森制药股份公司 | 用作聚(adp-核糖)聚合酶(parp)抑制剂的新型化合物 |
CN111995582B (zh) * | 2020-07-09 | 2021-12-03 | 天津理工大学 | 一种奥拉帕尼与尿素的共晶及其制备方法 |
CN111689905B (zh) * | 2020-07-22 | 2021-12-03 | 天津理工大学 | 一种奥拉帕尼与马来酸的共晶及其制备方法 |
WO2022058785A1 (en) * | 2020-09-16 | 2022-03-24 | Nuformix Technologies Limited | Olaparib oxalic acid cocrystals and their pharmaceutical use |
CN114249695A (zh) * | 2020-09-21 | 2022-03-29 | 齐鲁制药有限公司 | 一种奥拉帕利的新晶型、制备方法及用途 |
WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
CN114539161B (zh) * | 2020-11-11 | 2024-03-29 | 成都硕德药业有限公司 | 一种奥拉帕尼-尿素共晶及其制备方法 |
CN112500379B (zh) * | 2020-12-23 | 2024-01-23 | 南京方生和医药科技有限公司 | 一种奥拉帕利中间体及奥拉帕利的制备方法 |
CN112661733A (zh) * | 2020-12-23 | 2021-04-16 | 南京方生和医药科技有限公司 | 奥拉帕利杂质中间体、奥拉帕利杂质及其制备方法 |
CA3207488A1 (en) | 2021-01-08 | 2022-07-14 | Cybrexa 2, Inc. | Process for preparing a conjugate linking moiety |
WO2022155172A1 (en) | 2021-01-13 | 2022-07-21 | Cybrexa 3, Inc. | Peptide conjugates of therapeutics |
CN117321044A (zh) | 2021-04-08 | 2023-12-29 | 理森制药股份公司 | 聚(adp-核糖)聚合酶抑制剂 |
CN113636979B (zh) * | 2021-08-12 | 2023-06-13 | 天津理工大学 | 一种奥拉帕尼与富马酸共晶晶型α及其制备方法与应用 |
KR102645122B1 (ko) | 2021-08-25 | 2024-03-07 | 주식회사 보령 | 올라파립의 제조방법 |
CN115448886A (zh) * | 2022-10-11 | 2022-12-09 | 福建福瑞明德药业有限公司 | 一种奥拉帕利的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080976A1 (en) * | 2003-03-12 | 2004-09-23 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3813384A (en) | 1972-01-17 | 1974-05-28 | Asta Werke Ag Chem Fab | Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof |
US4665181A (en) | 1984-05-17 | 1987-05-12 | Pennwalt Corporation | Anti-inflammatory phthalazinones |
US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
US5032617A (en) | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
ES2031813T3 (es) | 1985-11-11 | 1993-01-01 | Asta Pharma Ag | Procedimiento para la preparacion de derivados de 4-bencil-1-(2h)-ftalazinona. |
JP2786896B2 (ja) | 1988-08-19 | 1998-08-13 | ワーナー―ランバート・コンパニー | 置換されたジヒドロイソキノリノンおよび関連化合物 |
DK0389995T3 (da) | 1989-03-28 | 1995-07-03 | Nisshin Flour Milling Co | Isoquinolinderivater til behandling af glaukom eller okular hypertension |
GB9011833D0 (en) | 1990-05-25 | 1990-07-18 | Collins Mary K L | Inhibition of viral infection |
MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
US6004979A (en) | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
CZ199593A3 (en) | 1992-10-02 | 1994-04-13 | Asta Medica Ag | Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr) |
AU5455194A (en) | 1992-11-02 | 1994-05-24 | Merck & Co., Inc. | Substituted phthalazinones as nerotensin antagonists |
EP0634404A1 (en) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Phtalazin derivatives and their use as pesticides |
US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
PT705902E (pt) | 1994-08-12 | 2002-05-31 | Univ Utah Res Found | Gene de susceptibilidade para o cancro da mama e do ovario, ligado a 17q. |
AU686004B2 (en) | 1994-08-12 | 1998-01-29 | Myriad Genetics, Inc. | In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene |
US5589483A (en) | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
US5834466A (en) | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
JP3038016B2 (ja) * | 1995-04-07 | 2000-05-08 | シェーリング コーポレイション | ファルネシルタンパク質トランスフェラーゼを阻害する、カルボニルピペラジニルおよびカルボニルピペリジニル化合物 |
US6127367A (en) | 1996-02-29 | 2000-10-03 | Pfizer, Inc. | Method of reducing tissue damage associated with non-cardiac ischemia |
US6080870A (en) | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5874452A (en) | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5872136A (en) | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
US5939557A (en) | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5854265A (en) | 1996-04-03 | 1998-12-29 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5859035A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
JP2000504023A (ja) * | 1996-04-03 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | 癌治療方法 |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
WO1997038664A2 (en) * | 1996-04-18 | 1997-10-23 | Merck & Co., Inc. | A method of treating cancer |
US5880128A (en) | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
JP2000508335A (ja) * | 1996-05-30 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | 癌の治療方法 |
US5854264A (en) | 1996-07-24 | 1998-12-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5888529A (en) | 1997-03-28 | 1999-03-30 | The Regents Of The University Of California | Ileus treatment method |
US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
WO1999008680A1 (en) | 1997-08-15 | 1999-02-25 | The Johns Hopkins University | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
US6426415B1 (en) | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
CA2310250A1 (en) | 1997-11-14 | 1999-05-27 | August Masaru Watanabe | Treatment for alzheimer's disease |
JP2002505288A (ja) | 1998-03-02 | 2002-02-19 | コセンシス,インコーポレイテッド | 置換キナゾリンおよびアナログならびにそれらの使用 |
US20040266784A1 (en) * | 1998-06-30 | 2004-12-30 | Snutch Terrance P. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
US6943168B2 (en) | 1998-06-30 | 2005-09-13 | Neuromed Technologies Inc. | Calcium channel inhibitors comprising benzhydril spaced from piperazine |
US6011035A (en) | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
US20040259866A1 (en) * | 1998-06-30 | 2004-12-23 | Snutch Terrance P. | Calcium channel blockers comprising two benzhydril moieties |
US6492375B2 (en) | 1998-06-30 | 2002-12-10 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
US6310059B1 (en) | 1998-06-30 | 2001-10-30 | Neuromed Technologies, Inc. | Fused ring calcium channel blockers |
US6387897B1 (en) | 1998-06-30 | 2002-05-14 | Neuromed Technologies, Inc. | Preferentially substituted calcium channel blockers |
US20060084660A1 (en) * | 1998-06-30 | 2006-04-20 | Neuromed Technologies Inc. | Calcium channel blockers comprising two benzhydril moieties |
US7186726B2 (en) * | 1998-06-30 | 2007-03-06 | Neuromed Pharmaceuticals Ltd. | Preferentially substituted calcium channel blockers |
US6951862B2 (en) * | 1998-06-30 | 2005-10-04 | Neuromed Technologies, Inc. | Calcium channel blockers comprising two benzhydril moieties |
AU3076700A (en) | 1999-01-26 | 2000-08-18 | Ono Pharmaceutical Co. Ltd. | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient |
DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
US6465467B1 (en) * | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
JP2003506446A (ja) | 1999-08-11 | 2003-02-18 | ブリストル−マイヤーズ スクイブ カンパニー | パクリタキセルc−4メチルカーボネート類縁体の製造法 |
US6465448B1 (en) | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
WO2001021615A1 (en) | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
BR0007174A (pt) | 1999-09-28 | 2001-09-04 | Basf Ag | Composto, preparação farmacêutica e uso de compostos |
US6552016B1 (en) | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
DE19963607B4 (de) | 1999-12-23 | 2005-12-15 | Schering Ag | Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen |
WO2001057038A1 (de) | 2000-02-01 | 2001-08-09 | Basf Aktiengesellschaft | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
WO2001079184A1 (fr) | 2000-04-18 | 2001-10-25 | Sumitomo Pharmaceuticals Company, Limited | Composes de piperazine substitues |
US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
US6723733B2 (en) | 2000-05-19 | 2004-04-20 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
US7498304B2 (en) * | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
AU7549501A (en) | 2000-06-16 | 2002-01-02 | Biogen Inc | Angiogenesis-modulating compositions and uses |
CN100400518C (zh) | 2000-10-30 | 2008-07-09 | 库多斯药物有限公司 | 2,3-二氮杂萘酮衍生物 |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
AU2002220241A1 (en) | 2000-12-01 | 2002-06-11 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
JPWO2002068407A1 (ja) | 2001-02-28 | 2004-06-24 | 山之内製薬株式会社 | ベンゾイミダゾール化合物 |
JP2004528376A (ja) | 2001-05-08 | 2004-09-16 | クドス ファーマシューティカルズ リミテッド | Parp阻害薬としてのイソキノリノン誘導体 |
EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
US20030073692A1 (en) * | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
RU2292337C2 (ru) | 2002-02-19 | 2007-01-27 | Оно Фармасьютикал Ко., Лтд. | Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
AU2003229953A1 (en) | 2002-04-30 | 2003-11-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) * | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
EP2305221B1 (en) | 2003-12-01 | 2015-05-20 | Kudos Pharmaceuticals Limited | DNA damage repair inhibitors for treatment of cancer |
EP1744751A4 (en) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | TREATMENT OF SYNUCLEINOPATHIES |
US20050227999A1 (en) * | 2004-04-09 | 2005-10-13 | Neuromed Technologies Inc. | Diarylamine derivatives as calcium channel blockers |
JP5315611B2 (ja) * | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7517870B2 (en) * | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
DE102005011822A1 (de) * | 2005-03-15 | 2006-09-21 | Merck Patent Gmbh | Phthalazinone |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
BRPI0722070A2 (pt) | 2006-12-28 | 2014-04-08 | Abbott Lab | Inibidores de poli(adp-ribose)polimerase |
TW200900396A (en) | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
WO2009050469A1 (en) | 2007-10-17 | 2009-04-23 | Kudos Pharmaceuticals Limited | 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one |
-
2007
- 2007-10-12 UY UY30639A patent/UY30639A1/es not_active Application Discontinuation
- 2007-10-12 TW TW096138353A patent/TWI404716B/zh active
- 2007-10-15 SI SI200730792T patent/SI2064189T1/sl unknown
- 2007-10-15 ES ES14181346.9T patent/ES2587129T3/es active Active
- 2007-10-15 KR KR1020147000557A patent/KR20140011425A/ko not_active Application Discontinuation
- 2007-10-15 AT AT07824140T patent/ATE528296T1/de active
- 2007-10-15 UA UAA200904210A patent/UA97494C2/ru unknown
- 2007-10-15 CA CA2875147A patent/CA2875147C/en active Active
- 2007-10-15 MX MX2009004103A patent/MX2009004103A/es active IP Right Grant
- 2007-10-15 ES ES07824140T patent/ES2372630T3/es active Active
- 2007-10-15 JP JP2009532883A patent/JP5248513B2/ja active Active
- 2007-10-15 PT PT07824140T patent/PT2064189E/pt unknown
- 2007-10-15 CN CN201210060660XA patent/CN102627611A/zh active Pending
- 2007-10-15 CN CN2007800388551A patent/CN101528714B/zh active Active
- 2007-10-15 CN CN201510002348.9A patent/CN104649979B/zh active Active
- 2007-10-15 ME MEP-2012-3A patent/ME01987B/me unknown
- 2007-10-15 EP EP07824140A patent/EP2064189B1/en active Active
- 2007-10-15 MY MYPI2013000334A patent/MY162829A/en unknown
- 2007-10-15 RU RU2009109068A patent/RU2465270C3/ru active Protection Beyond IP Right Term
- 2007-10-15 MY MYPI20091536A patent/MY147389A/en unknown
- 2007-10-15 SG SG10201408404XA patent/SG10201408404XA/en unknown
- 2007-10-15 BR BRPI0717125A patent/BRPI0717125B8/pt active IP Right Grant
- 2007-10-15 EP EP14181346.9A patent/EP2824098B1/en active Active
- 2007-10-15 NZ NZ575627A patent/NZ575627A/en unknown
- 2007-10-15 AU AU2007311766A patent/AU2007311766B2/en active Active
- 2007-10-15 EP EP11159495A patent/EP2374800A3/en not_active Withdrawn
- 2007-10-15 SG SG201009564-4A patent/SG168523A1/en unknown
- 2007-10-15 DK DK07824140.3T patent/DK2064189T3/da active
- 2007-10-15 PL PL07824140T patent/PL2064189T3/pl unknown
- 2007-10-15 CA CA2664275A patent/CA2664275C/en active Active
- 2007-10-15 KR KR20097007840A patent/KR101494910B1/ko active Protection Beyond IP Right Term
- 2007-10-15 WO PCT/GB2007/003888 patent/WO2008047082A2/en active Application Filing
- 2007-10-15 RS RS20120003A patent/RS52112B/en unknown
- 2007-10-16 CL CL200702967A patent/CL2007002967A1/es unknown
- 2007-10-16 PE PE2007001394A patent/PE20081175A1/es active IP Right Grant
- 2007-10-16 AR ARP070104583A patent/AR063320A1/es not_active Application Discontinuation
- 2007-10-17 US US11/873,671 patent/US7692006B2/en active Active
- 2007-10-20 SA SA07280551A patent/SA07280551B1/ar unknown
-
2009
- 2009-03-05 IL IL197420A patent/IL197420A/en active IP Right Grant
- 2009-05-12 CO CO09048110A patent/CO6210728A2/es not_active Application Discontinuation
- 2009-05-13 NO NO20091882A patent/NO341963B1/no unknown
- 2009-06-08 HK HK09105082.9A patent/HK1126483A1/xx unknown
- 2009-07-10 US US12/500,900 patent/US8247416B2/en active Active
-
2010
- 2010-08-23 SA SA110310666A patent/SA110310666B1/ar unknown
-
2011
- 2011-11-30 IL IL216705A patent/IL216705A/en active IP Right Grant
- 2011-12-29 CY CY20111101288T patent/CY1112345T1/el unknown
-
2012
- 2012-01-03 HR HR20120007T patent/HRP20120007T1/hr unknown
-
2013
- 2013-02-13 JP JP2013025205A patent/JP5607773B2/ja active Active
-
2014
- 2014-08-28 JP JP2014173377A patent/JP5719471B2/ja active Active
-
2015
- 2015-05-16 HK HK15104656.0A patent/HK1203959A1/zh unknown
-
2017
- 2017-11-09 NO NO20171775A patent/NO343063B1/no unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080976A1 (en) * | 2003-03-12 | 2004-09-23 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
Non-Patent Citations (1)
Title |
---|
Caira M. R., "Crystalline polymorphism of organic compounds" Topics in Current Chemistry, 1998, vol.198, pp.163-208. * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI404716B (zh) | 酞嗪酮(phthalazinone)衍生物 | |
US8183369B2 (en) | 4- [3- (4-cyclopropanecarbonyl-piperazine-I-carbonyl) -4 -fluoro-benzyl] -2H-phthalaz in-1-one | |
AU2013201880B2 (en) | Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one |